Marina Blanco Aparicio
Overview
Explore the profile of Marina Blanco Aparicio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Plaza Moral V, Alobid I, Alvarez Rodriguez C, Blanco Aparicio M, Ferreira J, Garcia G, et al.
Open Respir Arch
. 2023 Oct;
5(4):100277.
PMID: 37886027
The Spanish Guideline on the Management of Asthma, better known by its acronym in Spanish GEMA, has been available for more than 20 years. Twenty-one scientific societies or related groups...
2.
Casas-Maldonado F, Alvarez-Gutierrez F, Blanco Aparicio M, Ribas C, Cisneros Serrano C, Soto Campos G, et al.
Open Respir Arch
. 2023 Oct;
5(3):100252.
PMID: 37810425
Introduction And Objectives: The use of monoclonal antibody (mAb)-based therapies is becoming the new standard of care for severe uncontrolled asthma (SUA). Even though patients may qualify for one or...
3.
Padilla-Galo A, Moya Carmona I, Ausin P, Carazo Fernandez L, Garcia-Moguel I, Velasco-Garrido J, et al.
Respir Res
. 2023 Sep;
24(1):235.
PMID: 37770889
Background: The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain....
4.
Almonacid Sanchez C, Blanco Aparicio M, Dominguez Ortega J, Giner Donaire J, Molina Paris J, Sanchez Marcos N, et al.
Open Respir Arch
. 2023 Jul;
3(2):100098.
PMID: 37497073
Despite the therapeutic advances currently available, asthma control is poor. Such control is based on assessing the patient, adjusting treatment, and reviewing the response to treatment. In normal situations, asthma...
5.
Blanco Aparicio M, Dominguez-Ortega J, Hidalgo Requena A, Trigueros Carrero J, Urendez Ruiz A, Nunez Palomo S
Open Respir Arch
. 2023 Jul;
3(4):100130.
PMID: 37496845
No abstract available.
6.
Carretero Gracia J, Rodriguez Fernandez F, Gomez Saenz J, Molina Paris J, Gomez Ruiz F, Lopez Carrasco V, et al.
Open Respir Arch
. 2023 Jul;
3(4):100131.
PMID: 37496835
Asthma is one of the most prevalent chronic diseases in Spain. In 2019, the Spanish Society of Allergology and Clinical Immunology (SEAIC), the Spanish Society of Primary Care Physicians (SEMERGEN),...
7.
Hernandez L, Moreno R, Balaguer Cartagena M, Pelaez A, Sole A, Fernandez A, et al.
Arch Bronconeumol
. 2023 Jul;
59(9):556-565.
PMID: 37400317
Introduction: Elexacaftor/tezacaftor/ivacaftor (ETI) was used through the early access programme in Spain from December 2019 in cystic fibrosis (CF) patients with homozygous or heterozygous F508del mutation with advanced lung disease....
8.
Vilanova-Pereira M, Jacome C, Rial Prado M, Barral-Fernandez M, Blanco Aparicio M, Fontan Garcia-Boente L, et al.
PLoS One
. 2023 Mar;
18(3):e0281007.
PMID: 36893205
Background: Patients with asthma often consider their symptomatology a barrier to exercise, leading to a reduced physical activity level. This study aims to determine whether the effect of a Nordic...
9.
Hernandez L, Giron Moreno R, Pelaez A, Gomez Bonilla A, Gomez Crespo B, Diab Caceres L, et al.
Arch Bronconeumol
. 2022 Jul;
58(9):672-674.
PMID: 35781398
No abstract available.
10.
Perpina Tordera M, Alvarez Gutierrez F, Blanco Aparicio M
Arch Bronconeumol
. 2022 Apr;
58(5):390-391.
PMID: 35437205
No abstract available.